Riassunto: Opzelura® (ruxolitinib) crema diventa il primo inibitore mirato di JAK privo di steroidi approvato nell'Unione europea per adulti con dermatite atopica moderata
Wednesday, July 29, 2026 1 min read
Key Takeaway: Incyte has received approval from the European Commission for Opzelura (ruxolitinib) cream, marking it as the first steroid-free JAK inhibitor for moderate atopic dermatitis in adults. This treatment is specifically for patients who have not found relief with topical corticosteroids or calcineurin inhibitors. The approval represents a significant advancement in dermatological care for these patients in Europe.
Market Sentiment Analysis
POSITIVE FACTORS
Opzelura is the first steroid-free JAK inhibitor approved in the EU.
This approval provides a new treatment option for adults with moderate atopic dermatitis.
It addresses the needs of patients who have not responded to topical corticosteroids or calcineurin inhibitors.
Full Press Release Details
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) oggi ha annunciato che la Commissione europea (CE) ha approvato Opzelura® (ruxolitinib) crema per il trattamento della dermatite atopica (DA) moderata in pazienti adulti per i quali i corticosteroidi topici (TCS) e gli inibitori topici della calcineurina (TCI) non sono adeguati né adatti. "L'approvazione di Opzelura da parte della Commissione europea è una tappa importante per gli adulti in Europa che convivono con la dermatite atopica mod
Frequently Asked Questions
What is Opzelura used for?
Opzelura is used for treating moderate atopic dermatitis in adults.
Who approved Opzelura in the EU?
The European Commission approved Opzelura for use in the EU.
Is Opzelura a steroid-based treatment?
No, Opzelura is the first steroid-free JAK inhibitor approved for this condition.
What patients can use Opzelura?
It is for adults who have not responded to topical corticosteroids or calcineurin inhibitors.